Table 2.
Morphologic and functional CMR data of all study groups.
| Characteristic | Control (n = 20) | CA with pLVEF (n = 22) | CA with rLVEF (n = 18) | p-Value |
|---|---|---|---|---|
| LVEDVi, ml/m2 | 73.1 ± 12.5 | 71.2 ± 17.5 | 86.5 ± 23.4*,§ | 0.022 |
| LVESVi, ml/m2 | 23.7 ± 8.5 | 31.7 ± 18.8 | 56.5 ± 20.0*,§ | <0.001 |
| LVMWT, mm | 9.7 ± 1.3 | 16.4 ± 3.1* | 14.8 ± 2.13* | <0.001 |
| LVMi, g/m2 | 43.3 ± 7.8 | 75.5 ± 21.8* | 81.9 ± 22.9* | <0.001 |
| LVEF, % | 67.3 ± 10.2 | 59.4 ± 6.2* | 35.1 ± 9.1*,§ | <0.001 |
| CI, L•min−1/m2 | 3.4 ± 1.0 | 3.3 ± 0.7 | 2.5 ± 0.8*,§ | 0.007 |
*
Compared to the control group, adjusted p < 0.05.
§
Compared to the CA with pLVEF group, adjusted p < 0.05. p-Value referred to the overall comparison among three groups.
CA, cardiac amyloidosis; rLVEF, reduced left ventricular ejection fraction; pLVEF, preserved left ventricular ejection fraction; CMR, cardiac magnetic resonance; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic volume index; LVMWT, left ventricular maximal wall thickness; LVMi, left ventricular mass index; CI, cardiac index.